RIGAKU
3.9.2024 17:01:28 CEST | Business Wire | Press release
Rigaku Corporation, a Rigaku Holdings Group company and global partner for X-ray analysis from Lab to Fab (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has developed a technology called Electron Density Topography (“EDT”), patents pending. The new technology clarifies the structure and dynamic characteristics of biological macromolecules, including antibodies, protein complexes, and virus particles, in solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903386305/en/
EDT device (Photo: Business Wire)
EDT enables direct observation of biological macromolecules in solution, reducing artifacts resulting from measurement conditions. EDT is anticipated to improve the R&D processes for innovative biopharmaceuticals, including monoclonal antibody-based therapies and advanced drug delivery systems.
EDT provides information about the overall shape, molecular characteristics and internal structure of biological macromolecules from the distribution of electrons that determines a molecule's chemical properties. EDT has also enabled direct observation of the electron density of biological macromolecules without prior information about the samples.
In drug discovery, there is a clear need to determine at the early stages of development whether a drug has the expected structure and desired characteristics to optimize resources. EDT is a technology that meets this requirement and is expected to be used in basic research and development for biopharmaceuticals such as antibody drugs.
The first instrument with EDT capabilities will be deployed at Rigaku's Life Science Laboratory, a facility in Cambridge, Massachusetts, in Q4 2024.
Rigaku is committed to expanding its operations in the life sciences field, strengthening its presence to drive further innovation in collaboration with customers.
About The Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903386305/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom